News Centres

Mumbai, India – The leadership team of Influx Healthtech Ltd. recently participated in the Bharat Conclave 2026 – Emerging Leaders Conference, a prominent virtual investor platform designed to connect promising Indian companies with investors, analysts, and financial market participants. The conference provided an opportunity for emerging growth companies to present…

Influx Healthtech Ltd., is a leading Contract Development and Manufacturing Organization (CDMO) in the nutraceutical, cosmeceutical, and veterinary supplement sector, has achieved a significant international milestone by receiving approval from the Tanzania Bureau of Standards (TBS) for its nutraceutical manufacturing operations. This accomplishment places Influx Healthtech among the few Indian…

Liposomal Ingredients in Formulations Helps Brands Deliver Better Absorption, Better Outcomes, and Better Market Differentiation The nutraceutical industry is undergoing a significant transformation. Today’s consumers are more informed than ever and increasingly demand supplements that are not only safe and compliant, but also scientifically effective and visibly impactful. In response…

With the launch of Ozempic (semaglutide) in India, GLP-1 medicines have officially entered mainstream clinical practice for Type 2 diabetes management—bringing with them a big opportunity and a big responsibility: medication works best when nutrition is planned, not accidental. GLP-1 therapies are powerful because they help improve glycaemic control and…

Influx Healthtech’s CEO and CMD, Dr. M.A. Chandniwala, recently represented the company at Alpha Ideas 2025, a prestigious investor meet held in Mumbai. The event is known for bringing together promising companies and connecting them with an exclusive audience of investors, analysts, and market participants. It provides a platform for…

Influx Healthtech Ltd, a leading CDMO (Contract Development and Manufacturing Organization) in the wellness and healthcare space, has received a significant repeat export order valued at approximately ₹1.2 crore from merchant exporter Octavius Pharma Pvt Ltd for the Sudanese market. This development marks yet another milestone in Influx’s growing global…

Influx Healthtech Ltd. is proud to announce that it has successfully completed the mandatory Good Manufacturing Practices (GMP) audit mandated by the Food Safety and Standards Authority of India (FSSAI), earning the prestigious A+ Exemplar grade. This certification highlights the company’s unwavering commitment to quality, safety, and regulatory compliance in…

Influx Healthtech Ltd, has achieved a milestone by receiving the FSSAI Form II approval for the use of Magnesium Glycinate in tablet, capsule, and liquid preparations. This approval, granted by the FSSAI Scientific Committee, reinforces Influx Healthtech’s commitment to innovation and regulatory compliance. Magnesium Glycinate is a highly bioavailable form…